Employees: 329
Size Alembic (ALEMBICLTD.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $309M, the 1054th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹112.41 on 18 Nov 2026.
Performance Over six months the shares gained 25.1%, against -22.8% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 4.7% over the last twelve months (peer median +2.9%); the operating margin is 26.2% (peer median -1.9%).
Valuation It trades at 13.0× enterprise value to sales against a peer median of 4.1× (5th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 16.5 points below its cost of capital (18.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹2.13B | ₹2.40B | ₹2.22B | ₹1.57B | ₹1.27B |
| Revenue growth | — | +8% | +41% | +24% | — |
| Gross profit | ₹941M | ₹1.02B | ₹1.03B | ₹734M | ₹496M |
| EBITDA | ₹698M | ₹919M | ₹942M | ₹571M | ₹405M |
| Net income | ₹3.55B | ₹3.17B | ₹3.11B | ₹2.69B | ₹1.91B |
| Free cash flow | n/a | ₹1.06B | ₹981M | ₹132M | ₹705M |
| Capital expenditure | n/a | ₹767M | ₹508M | ₹563M | ₹258M |
| Total debt | ₹0 | ₹106M | ₹144M | ₹91.5M | ₹0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALEMBICLTD.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.1% | -9.7% | 3rd highest of 21 |
| 6-month return | +25.1% | -22.8% | 4th highest of 21 |
| Distance from 52-week high | -4.9% | -38.0% | highest of 21 |
| Revenue growth (TTM) | -4.7% | +2.9% | 5th lowest of 19 |
| Operating margin | 26.2% | -1.9% | 2nd highest of 19 |
| EV / Sales | 13.0× | 4.1× | 5th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 44.3% | 6.1% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +26.7% | +2.3% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | +17.6 pp | +4.9 pp | 4th most demanding of 12 |
| ROIC minus cost of capital | -16.5 pp | -7.0 pp | 6th lowest of 18 |
| EV / EBITDA | 39.6× | 9.6× | most expensive of 6 |
| Net debt / EBITDA | -1.8× | -0.6× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | 13.0× | 44.3% | +26.7% |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | 2.1× | 14.0% | +7.3% |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | 5.6× | 27.5% | -6.4% |
| Hinova Pharmaceuticals 688302.SS | China | $305M | -35% | +251% | -195% | 17.1× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $305M | -60% | n/a | n/a | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | 3.4× | n/a | n/a |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | 921.6× | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 3.1× | -16.8% | +5.4% |
| Honz Pharmaceutical 300086.SZ | China | $299M | -40% | -23% | -54% | 7.3× | 56.0% | -12.8% |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | 1.1× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 1.8× | 6.1% | +62.1% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $297M | -30% | -3% | 7% | 2.3× | 4.6% | -0.3% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | 21.4× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $296M | -21% | -32% | -58% | 4.8× | 1.4% | -4.9% |
| OBI Pharma 4174.TWO | Taiwan | $295M | +135% | -2% | -2,968% | 214.0× | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | 6.2× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | 7.4× | 14.3% | -14.0% |
| Shandong Sito Bio-technology 300583.SZ | China | $292M | -30% | +19% | 6% | 2.3× | 1.6% | +2.3% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | 1.8× | -11.5% | +10.3% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | 1.4× | 9.2% | +6.5% |